Bosulif

Chemical Namebosutinib
Dosage FormTablet (oral; 100 mg, 500 mg)
Drug ClassKinase inhibitors
SystemBlood
CompanyPfizer
Approval Year2012

Indication

  • For the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy
  • For the treatment of adult patients with newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML)
Last updated on 4/21/2022

More on this drug: Clinical Trials

Document TitleYearSource
Bosulif (bosutinib) Prescribing Information.2012Pfizer Inc., New York, NY
Document TitleYearSource
Chronic myeloid leukemia, version 2.2021.2020Journal of the National Comprehensive Cancer Network
Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.2017Annals of Oncology

Have we missed a study, or would you like to comment on a study?